PRODUCT FLYERS
Bachem offers for free a series of flyers on selected groups of products in peptide research.
Flyers
 | alpha-Methyl Amino AcidsBachem’s portfolio of α-methyl amino acids has been extended by a set of new innovative products, produced by our partner DOTTIKON Exclusive Synthesis AG. α-Methyl amino acids can be obtained by various methods such as Cα-methylation of N,N-disubstituted amino acid derivatives in the presence of a chiral catalyst. The proprietary approach of Maruoka et al. starting from N-p-chlorobenzylidene amino acid esters is especially suited for the modification of aromatic amino acids. A biphenyl-derived chiral phase-transfer catalyst promotes enantioselective alkylation. |
| (pdf, 297 KB) | |
| Download | |
 | ExenatideBachem, the world’s leading manufacturer of peptide active pharmaceutical ingredients, is your reliable source for exenatide and other GLP-1 agonists. |
| (pdf, 91 KB) | |
| Download | |
 | Impurities in Peptide APIsImpurities observed in peptide APIs can be process related impurities, which cannot be removed completely during purification of the crude peptide or product related impurities that are formed as degradation products during storage. Typically these impurities are byproducts resulting from side reactions occurring during the syntheses, such as racemization, deamidation, oxidation or aspartimide formation. Peptide APIs obtained by solid-phase synthesis may additionally contain analogs resulting from deletion or double insertion of amino acids. References of such compounds are needed for analytical method development and release testing, because fulfilling the specifications for byproducts is required by the relevant pharmacopeia and, most importantly, for ensuring the quality of the API. |
| (pdf, 303 KB) | |
| Download | |
 | Impurities in Peptide APIs (Janpanese)Impurities observed in peptide APIs can be process related impurities, which cannot be removed completely during purification of the crude peptide or product related impurities that are formed as degradation products during storage. Typically these impurities are byproducts resulting from side reactions occurring during the syntheses, such as racemization, deamidation, oxidation or aspartimide formation. Peptide APIs obtained by solid-phase synthesis may additionally contain analogs resulting from deletion or double insertion of amino acids. References of such compounds are needed for analytical method development and release testing, because fulfilling the specifications for byproducts is required by the relevant pharmacopeia and, most importantly, for ensuring the quality of the API. |
| (pdf, 409 KB) | |
| Download | |
 | LanreotideThe long-acting somatostatin agonist Lanreotide (INN) was initially developed for the management of acromegaly, for which it has been approved in many countries. Consecutive studies showed that lanreotide alleviates symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome, and can serve as an alternative to octreotide in this field. Interestingly, lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogs, is being studied as a possible general anti-tumor agent. |
| (pdf, 88 KB) Bachem | |
| Download | |
 | Oligonucleotides APIs MicrosynthSeveral antisense oligonucleotide drugs have been approved by the regulatory agencies (FDA, EMEA) in the past two decades. Oligonucleotide-based therapeutics generally are a hot topic in research and development as they open the door for the treatment of a broad range of diseases that cannot be treated differently. Two pioneers in the industry, Microsynth AG and Bachem AG, with long-term experience in catering to the phamaceutical industry as well as research organizations, offer the full portfolio of services and products needed to successfully develop, launch and market oligonucleotide APIs. |
| (pdf, 152 KB) | |
| Download | |
 | Periodic Chart of Amino AcidsWe are pleased to present our Periodic Chart of Amino Acids. |
| (pdf, 345 KB) | |
| Download | |
 | Teplows PeptidesOur new partner, the Teplow laboratory seeks to understand and treat diseases associated with the aging process. Teplow’s Amyloid β-Protein (1-42) and Teplow’s Amyloid β-Protein (1-40), our “Teplow`s Peptides”, are new negative control peptides, designed by the Teplow laboratory for studies towards the aggregation behavior of Aβ. |
| (pdf, 167 KB) | |
| Download | |
Page:
